BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry

BRCA1 and BRCA2 (BRCA1/2) pathogenic sequence variants (PSVs) confer elevated risks of multiple cancers. However, most BRCA1/2 PSVs reports focus on European ancestry individuals. Knowledge of the PSV distribution in African descent individuals is poorly understood. We undertook a systematic review of the published literature and publicly available databases reporting BRCA1/2 PSVs also accessed the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) database to identify African or African descent individuals. Using these data, we inferred which of the BRCA PSVs were likely to be of African continental origin. Of the 43,817 BRCA1/2 PSV carriers in the CIMBA database, 469 (1%) were of African descent. Additional African descent individuals were identified in public databases (n = 291) and the literature (n = 601). We identified 164 unique BRCA1 and 173 unique BRCA2 PSVs in individuals of African ancestry. Of these, 83 BRCA1 and 91 BRCA2 PSVs are of likely or possible African origin. We observed numerous differences in the distribution of PSV type and function in African origin versus non‐African origin PSVs. Research in populations of African ancestry with BRCA1/2 PSVs is needed to provide the information needed for clinical management and decision‐making in African descent individuals worldwide.

[1]  T. Walsh,et al.  Inherited Breast Cancer in Nigerian Women , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Mzibri,et al.  BRCA1 c.68_69delAG (exon2), c.181T>G (exon5), c.798_799delTT and 943ins10 (exon11) mutations in Burkina Faso , 2018, Journal of public health in Africa.

[3]  Annette Lee,et al.  Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations , 2018, Human mutation.

[4]  M. Sekine,et al.  Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan , 2017, Journal of Human Genetics.

[5]  M. Hassan,et al.  Monoallelic characteristic-bearing heterozygous L1053X in BRCA2 gene among Sudanese women with breast cancer , 2017, BMC Medical Genetics.

[6]  S. Grover,et al.  An update on the management of breast cancer in Africa , 2017, Infectious Agents and Cancer.

[7]  Olufunmilayo I. Olopade,et al.  Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women , 2016, Breast Cancer Research.

[8]  S. Narod,et al.  A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago , 2016, Breast Cancer Research and Treatment.

[9]  A. Monteiro,et al.  A high frequency of BRCA mutations in young black women with breast cancer residing in Florida , 2015, Cancer.

[10]  A. Vral,et al.  BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer , 2015, BMC Cancer.

[11]  C. Isaacs,et al.  Deleterious BRCA1/2 mutations in an urban population of Black women , 2015, Breast Cancer Research and Treatment.

[12]  T. Walsh,et al.  Inherited predisposition to breast cancer among African American women , 2014, Breast Cancer Research and Treatment.

[13]  E. van Limbergen,et al.  From the set-up of a screening program of breast cancer patients to the identification of the first BRCA mutation in the DR Congo , 2014, BMC Public Health.

[14]  P. Blasio,et al.  BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan , 2014, Familial Cancer.

[15]  Akbari,et al.  The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas , 2014, Clinical genetics.

[16]  M. Mzibri,et al.  Breast cancer in Morocco: a literature review. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[17]  Soo-Hwang Teo,et al.  Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations , 2012, European Journal of Human Genetics.

[18]  Lawal AbdulRazzaq Oluwagbemiga,et al.  Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? – a systematic review , 2012, SpringerPlus.

[19]  O. Olopade,et al.  High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients , 2012, International journal of cancer.

[20]  M. C. Leske,et al.  Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry , 2012, Breast Cancer Research and Treatment.

[21]  W. Foulkes,et al.  A founder BRCA2 mutation in non‐Afrikaner breast cancer patients of the Western Cape of South Africa , 2012, Clinical genetics.

[22]  O. Díez,et al.  Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer. , 2011, Oncology letters.

[23]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[24]  O. Olopade,et al.  Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population , 2010, Breast Cancer Research and Treatment.

[25]  R. Janavicius.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control , 2010, EPMA Journal.

[26]  S. Narod,et al.  A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas , 2010, Breast Cancer Research and Treatment.

[27]  D. Toppmeyer,et al.  Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  B. Ward,et al.  BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer , 2009, Cancer.

[29]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[30]  S. Vadaparampil,et al.  BRCA1/2 in high-risk African American women with breast cancer: providing genetic testing through various recruitment strategies. , 2008, Genetic testing.

[31]  Olga Anczuków,et al.  Does the nonsense‐mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? , 2008, Human mutation.

[32]  C. Adebamowo,et al.  Evidence for an ancient BRCA1 mutation in breast cancer patients of yoruban ancestry , 2008, Familial Cancer.

[33]  B. Kingham,et al.  BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer , 2008, Breast Cancer Research and Treatment.

[34]  Alice S Whittemore,et al.  Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. , 2007, JAMA.

[35]  Georgia Chenevix-Trench,et al.  An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) , 2007, Breast Cancer Research.

[36]  T. Rebbeck,et al.  Prophylactic oophorectomy in women at increased cancer risk , 2007, Current opinion in obstetrics & gynecology.

[37]  R. Mariani-Costantini,et al.  BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors , 2007, Breast Cancer Research and Treatment.

[38]  Olga Anczuków,et al.  The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon , 2006, Human mutation.

[39]  O. Olopade,et al.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. , 2006, The Lancet. Oncology.

[40]  T. Rebbeck,et al.  Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[41]  S. Tavtigian,et al.  Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? , 2006, Oncogene.

[42]  O. Olopade,et al.  Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  L. Esserman,et al.  Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. , 2005, JAMA.

[44]  C. Rotimi,et al.  Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients , 2005, Journal of Medical Genetics.

[45]  R. Sutphen,et al.  BRCA1 and BRCA2 mutations in a study of African American breast cancer patients. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  Thorunn Rafnar,et al.  The Icelandic founder mutation BRCA2 999del5: analysis of expression , 2004, Breast Cancer Research.

[47]  G. Dunston,et al.  Inherited BRCA2 mutations in African Americans with breast and/or ovarian cancer: a study of familial and early onset cases , 2003, Human Genetics.

[48]  O. Olopade,et al.  Breast cancer genetics in African Americans , 2003, Cancer.

[49]  D. Stoppa-Lyonnet,et al.  The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. , 2002, Human molecular genetics.

[50]  Olufunmilayo I. Olopade,et al.  Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer , 2000, Human Genetics.

[51]  J. Vadgama,et al.  Mutation analysis of BRCA1 gene in African-American patients with breast cancer. , 2000, Journal of the National Medical Association.

[52]  A. Godwin,et al.  Novel germline BRCA1 mutation (155del4) in an African American with early‐onset breast cancer , 1999, Human mutation.

[53]  R. Modali,et al.  BRCA1 mutations in African Americans , 1999, Human Genetics.

[54]  A. Ganguly,et al.  High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families , 1998, Human Genetics.

[55]  P. Laurent-Puig,et al.  BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. , 1997, American journal of human genetics.

[56]  S. Cummings,et al.  Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. , 1997, American journal of human genetics.

[57]  Francis S. Collins,et al.  Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer , 1994, Nature Genetics.

[58]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[59]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.